QIAGEN announced on June 2, 2025, the expansion of its oncology diagnostics portfolio through two strategic partnerships aimed at advancing minimal residual disease (MRD) testing in clinical trials. These collaborations with Tracer Biotechnologies and Foresight Diagnostics will cover both solid tumors and hematological cancers.
MRD testing is becoming a cornerstone of oncology, enabling early detection of cancer recurrence and guiding timely adjustments to therapy from blood samples. The partnership with Tracer Biotechnologies focuses on co-developing and commercializing MRD assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform.
The collaboration with Foresight Diagnostics involves developing a kit-based version of its CLARITY™ assay for lymphoma and other hematological malignancies. These partnerships strengthen QIAGEN’s scalable, cost-effective solutions and its role in bringing innovative MRD technologies into clinical practice to support personalized cancer care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.